SAN DIEGO, Dec. 7, 2022 /PRNewswire/ -- Element Biosciences, Inc.—developer of an innovative DNA sequencing platform that is disrupting the genomics industry—today announced Avidity Cloudbreak ...
Element Biosciences, the developer of the AVITI benchtop sequencer, will be sharing details about its technology and discussing customer stories at the annual meeting of the American Society of Human ...
VENLO, Netherlands, and SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Element Biosciences, Inc. today announced a strategic partnership to offer ...
SAN DIEGO and HERCULES, Calif., Feb. 8, 2023 /PRNewswire/ -- Element Biosciences, Inc. — the developer of an innovative DNA sequencing platform disrupting genomics — and Bio-Rad Laboratories, Inc.
The Element AVITI Sequencing Platform’s novel Avidity Sequencing chemistry can be easily adapted for use with the Bio-Rad SEQuoia Complete Stranded RNA Library Prep Kit and the SEQuoia Express ...
Companies unite in shared vision of enabling researchers to translate genomic insights to groundbreaking discoveries Partnership includes launch of new IDT xGen™ NGS products designed exclusively for ...
Shawn Levy (left) is Chief Scientific Officer and Senior Vice President of Applications at Element Biosciences (CA, USA), leading a multidisciplinary team supporting applications development and ...
Partnership combines QIAGEN's QIAseq panels, CLC LightSpeed, and QCI Interpret software to support Element's AVITI System users in genomic analysis Element and QIAGEN are advancing genomic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results